Mood Stabilizers in Patients with Elevated LFTs
Lithium is the preferred mood stabilizer when liver function tests are elevated, as it undergoes renal elimination without hepatic metabolism. 1
Primary Recommendation: Lithium
Lithium should be your first-line choice because it bypasses the liver entirely—it's eliminated unchanged by the kidneys 1. This makes it the safest option when hepatic function is already compromised. However, you must ensure adequate renal function before initiating therapy, as lithium has a narrow therapeutic window and requires careful monitoring of serum levels, renal function, and thyroid function every 3-6 months 2.
Baseline Requirements for Lithium:
- Complete blood count
- Thyroid function tests
- Urinalysis
- BUN, creatinine, and serum calcium
- Pregnancy test in females 2
Second-Line Options: Newer Anticonvulsants with Minimal Hepatic Metabolism
If lithium is contraindicated or ineffective, consider lamotrigine as your next choice. While lamotrigine does undergo some hepatic metabolism, it has a more favorable hepatic safety profile compared to valproate or carbamazepine 3. The critical caveat is the need for slow titration to avoid Stevens-Johnson syndrome 3.
Agents to AVOID with Elevated LFTs
Do not use valproate, carbamazepine, or felbamate when LFTs are already elevated 4. These agents undergo extensive hepatic metabolism and carry well-recognized hepatotoxicity risks:
Valproate: Despite having the "most favorable adverse effect profile" in patients with normal liver function 3, it requires baseline and periodic liver function monitoring 2 and should be avoided when LFTs are already abnormal. Valproate can cause hyperammonemia and hepatotoxicity 3.
Carbamazepine: Frequently causes liver dysfunction through allergic mechanisms 3 and undergoes extensive hepatic metabolism 4.
Felbamate: Has well-recognized hepatotoxicity and should be used only as a last resort even in patients with normal liver function 4.
Important Clinical Considerations
Monitoring Strategy
Even with lithium, you cannot ignore the liver entirely. The evidence shows that clinical monitoring for signs and symptoms of hepatotoxicity is more important than routine laboratory testing for detecting severe liver injury 5. Watch for:
- Jaundice
- Right upper quadrant pain
- Unexplained fatigue or malaise
- Dark urine or pale stools
Atypical Antipsychotics as Adjuncts
If you're considering adding an atypical antipsychotic for mood stabilization, be aware that olanzapine carries hepatotoxicity risk (24.2% prevalence in one recent study) 6, with higher daily doses and elevated baseline GGT as independent risk factors 6. The hepatotoxicity is typically mild and reversible with discontinuation 6.
Common Pitfall
Don't assume that "mild asymptomatic elevations" in LFTs predict progression to severe injury—they usually don't 5. However, this doesn't mean you should use hepatotoxic agents when LFTs are already elevated. The key is choosing agents that don't add additional hepatic burden.
Dose Optimization
Regardless of which agent you choose, use the lowest effective dose 7. Most adverse effects are dose-related and transient 7, so aggressive up-titration in a patient with compromised liver function is particularly risky.
Algorithm Summary
- First choice: Lithium (if renal function adequate)
- Second choice: Lamotrigine (with slow titration)
- Avoid entirely: Valproate, carbamazepine, felbamate
- Monitor clinically: Watch for hepatotoxicity symptoms, not just lab values
- Use lowest effective doses: Minimize all medication burden on compromised liver